NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Learn more

Workspace · Cancer algorithms · Myeloma

Myeloma

Myeloma · 36,000 new · 10,850 deaths (ACS 2026) · mortality 2.8 per 100k · 5-yr RS 63.7% (SEER)

Mortality 2.8 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 0.8% (SEER Stat Facts). 202,793 people living with myeloma in 2023. Separate from the NHL heme stub and from leukemia. No invented incidence formula.

202,793 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 69 · at death 76 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 9.1 / women 6.1 per 100k · mortality men 3.6 / women 2.3 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases stable (2014–2023). Death rates falling 3.0% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic Black men 17.9 per 100k. Highest death rate: Non-Hispanic Black men 6.7 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
GroupInc. menInc. womenDeaths menDeaths women
Hispanic8.35.82.81.9
Non-Hispanic American Indian/Alaska Native8.65.43.52.1
Non-Hispanic Asian/Pacific Islander5.23.51.71.2
Non-Hispanic Black17.913.46.74.6
Non-Hispanic White8.45.23.42.0

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2025 · Most people without a named higher-risk context · ACS (2025): there are no recommended screening tests to look for multiple myeloma in most people. Higher-risk watching is named but not encoded. Not a serum-protein screening engine.

Cited ACS statement only. Not a screening engine. ACS-myeloma-detect

Surveillance pointer

ACS-myeloma-follow 2025 · cited only · ACS living-as-a-survivor page says to go to all follow-up appointments during and after treatment. Visits may include symptoms, exam, blood or urine tests, or PET/CT or MRI. Those months are not encoded. Not a myeloma M-protein engine.

Named public source only. Not a personal follow-up calendar. ACS-myeloma-follow

Surveillance pointer

ACS-myeloma-follow 2025 · cited only · ACS living-as-a-survivor page names later cancers after myeloma, including AML and MDS. Those named later cancers are not encoded. Complementary to the living-as pointer. Not a myeloma M-protein or PET/CT engine. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-myeloma-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names a cancer treatment summary and survivorship care plan, plus peripheral neuropathy after chemo and cancer-related fatigue. Those names are not encoded. Complementary to the living-as pointer. Not a myeloma M-protein or PET/CT engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Echoes after cardiotoxic chemo and lung function tests after some chemo or a stem-cell or bone-marrow transplant are named. Those plans and tests are not encoded. Complementary to the lymphoma/myeloma printout. Anthracycline and bleomycin stay unnamed here as myeloma-specific. The cited adult living-as page still has no named late-effect list of its own beyond a treatment summary. Not a myeloma M-protein or PET/CT engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Anthracycline and bleomycin stay unnamed as myeloma-specific.

Toxicity pointer

ACS-myeloma-follow 2025 · empty on purpose · ACS living-as-a-survivor page names treatment side effects. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-myeloma-follow

Toxicity pointer

ACS-myeloma-follow 2025 · empty on purpose · ACS living-as-a-survivor page names later cancers after myeloma, including AML and MDS. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-myeloma-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later peripheral neuropathy after chemo and cancer-related fatigue. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching, plus echoes after cardiotoxic chemo and lung function tests after some chemo or transplant. Those named tests are not encoded. Complementary to the lymphoma/myeloma printout. Anthracycline and bleomycin stay unnamed here as myeloma-specific. Not a myeloma M-protein or PET/CT engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Anthracycline and bleomycin stay unnamed as myeloma-specific.

Late toxicity printout

Late toxicity printout — Lymphoma / myeloma fields

Acute: ACS names fatigue, field skin change, sore throat, nausea, and low blood counts. Late: heart and lung problems after chest-field RT or named cardiotoxic or lung-toxic drugs, thyroid problems after neck-field RT, breast-imaging after chest RT, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, fertility effects, sexuality changes, neuropathy after chemo, and cognitive change after chemo. Monitor: COG / ASCO echo flags; yearly thyroid exam; lung function tests after some chemo or transplant; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; numbness or tingling after chemo; memory, thinking, or focus change after chemo. Those names are not encoded. Hodgkin stays Ann Arbor. Official Stage I percent-of-cases cells are not restated. Anthracycline and bleomycin stay unnamed as myeloma-specific. Not an AML or PET/CT engine.

Anthracycline and bleomycin stay unnamed as myeloma-specific.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

  • Heart problems after anthracyclines or chest RT
  • Lung problems after bleomycin or chest RT
  • Second cancers after chemo or chest RT
  • Cancer-related fatigue that lasts
  • Joint or muscle pain after some treatments
  • Mental health and distress after treatment
  • Bowel or bladder problems after abdomen or pelvis treatment
  • Hearing loss after high-dose platinum chemo
  • Cavities and tooth loss after chemo
  • Peripheral neuropathy after chemo
  • Cognitive impairment after brain RT or chemo
  • Heart problems after some cardiotoxic treatments
  • Low thyroid hormones after head or neck radiation
  • Lung problems after bleomycin, busulfan, or chest RT
  • Fertility after pelvis, belly, or spine RT
  • Sexuality after cancer treatment

ACS follow-up tests named here

Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30

Named conditions to monitor

  • Anthracycline echo and chest-RT flags
  • Breast imaging after chest RT before age 30
  • Second-cancer testing
  • Cardiologist or pulmonologist after named cardiotoxic or lung-toxic treatment
  • Cancer-related fatigue or sleep problems that last
  • Joint or muscle pain after chemo, steroids, or hormone therapy
  • Anxiety, depression, or fear of recurrence after treatment
  • Bowel or bladder change after abdomen or pelvis treatment
  • Hearing change after high-dose platinum chemo
  • Cavity risk after chemo
  • Numbness or tingling in the feet or hands after chemo
  • New or worsening memory, thinking, or focus
  • New heart symptoms years after cardiotoxic treatment
  • Fatigue, hair loss, or feeling colder after head or neck radiation
  • Cough, shortness of breath, or wheezing after lung-toxic treatment
  • Fertility after pelvis, belly, or spine treatment
  • Sexuality or body-image change after treatment
  • Second-cancer awareness after radiation or chemo
  • Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS / COG / ASCO field names only. Complementary ACS long-term page is named, not encoded. Hodgkin stays Ann Arbor, not localized/regional/distant. No dose reconstruction. Official Stage I percent-of-cases cells are not restated.

Open Lymphoma / myeloma fields printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-myeloma · stub · none · v2-stub-myeloma

SEER 5-year relative survival by stage (cited stub)

Localized 82.1% · Regional 80.7% · Distant 63.0% · All 63.7%

Most cases present distant. Not an ISS formula.

Percent of cases by stage (SEER Stat Facts)

Localized 3% · Regional 0% · Distant 96% · Unknown 0%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Most cases present distant. Not an ISS formula.

  • lifetime

    Myeloma birth-to-death

    ≈ 0.8%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    ACS — no recommended myeloma screen for most people

    Cited ACS 2025 statement only. Not a serum-protein screening engine.

    not encoded

  • surveillance

    ACS follow-up cited — myeloma months not encoded

    Cited ACS living-as-a-survivor page only. Not a myeloma M-protein engine.

    not encoded

  • toxicity

    ACS late effects cited — myeloma months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    ACS — no recommended myeloma screen for most people

    Cited ACS 2025 statement only. Not a serum-protein screening engine.

    not encoded

  • surveillance

    ACS follow-up cited — myeloma months not encoded

    Cited ACS living-as-a-survivor page only. Not a myeloma M-protein engine.

    not encoded

  • toxicity

    ACS late effects cited — myeloma months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    ACS — no recommended myeloma screen for most people

    Cited ACS 2025 statement only. Not a serum-protein screening engine.

    not encoded

  • surveillance

    ACS follow-up cited — myeloma months not encoded

    Cited ACS living-as-a-survivor page only. Not a myeloma M-protein engine.

    not encoded

  • toxicity

    ACS late effects cited — myeloma months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    ACS — no recommended myeloma screen for most people

    Cited ACS 2025 statement only. Not a serum-protein screening engine.

    not encoded

  • surveillance

    ACS follow-up cited — myeloma months not encoded

    Cited ACS living-as-a-survivor page only. Not a myeloma M-protein engine.

    not encoded

  • toxicity

    ACS late effects cited — myeloma months not encoded

    Empty on purpose. Named ACS side effects are not encoded.

    not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →